Katie Doores
#166,366
Most Influential Person Now
British biochemist
Katie Doores's AcademicInfluence.com Rankings
Katie Dooresbiology Degrees
Biology
#14285
World Rank
#17998
Historical Rank
Biochemistry
#2657
World Rank
#2839
Historical Rank
Download Badge
Biology
Katie Doores's Degrees
- PhD Biochemistry University of Oxford
- Bachelors Biochemistry University of Oxford
Why Is Katie Doores Influential?
(Suggest an Edit or Addition)According to Wikipedia, Katherine Jane Doores is a British biochemist who is a senior lecturer in the School of Immunology & Microbial Sciences at King's College London. During the COVID-19 pandemic Doores studied the levels of antibodies in patients who had suffered from COVID-19.
Katie Doores's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- Broad neutralization coverage of HIV by multiple highly potent antibodies (2011) (1428)
- Longitudinal observation and decline of neutralizing antibody responses in the three months following SARS-CoV-2 infection in humans (2020) (963)
- A Potent and Broad Neutralizing Antibody Recognizes and Penetrates the HIV Glycan Shield (2011) (691)
- A dynamic COVID-19 immune signature includes associations with poor prognosis (2020) (689)
- Safety and immunogenicity of one versus two doses of the COVID-19 vaccine BNT162b2 for patients with cancer: interim analysis of a prospective observational study (2021) (363)
- Broadly neutralizing HIV antibodies define a glycan-dependent epitope on the prefusion conformation of gp41 on cleaved envelope trimers. (2014) (350)
- Supersite of immune vulnerability on the glycosylated face of HIV-1 envelope glycoprotein gp120 (2013) (329)
- Envelope glycans of immunodeficiency virions are almost entirely oligomannose antigens (2010) (320)
- Broadly Neutralizing Antibody PGT121 Allosterically Modulates CD4 Binding via Recognition of the HIV-1 gp120 V3 Base and Multiple Surrounding Glycans (2013) (283)
- Peripheral immunophenotypes in children with multisystem inflammatory syndrome associated with SARS-CoV-2 infection (2020) (275)
- Variable Loop Glycan Dependency of the Broad and Potent HIV-1-Neutralizing Antibodies PG9 and PG16 (2010) (235)
- The Glycan Shield of HIV Is Predominantly Oligomannose Independently of Production System or Viral Clade (2011) (219)
- Composition and Antigenic Effects of Individual Glycan Sites of a Trimeric HIV-1 Envelope Glycoprotein (2016) (217)
- Promiscuous Glycan Site Recognition by Antibodies to the High-Mannose Patch of gp120 Broadens Neutralization of HIV (2014) (183)
- The effect of spike mutations on SARS-CoV-2 neutralization (2021) (150)
- Exploring and exploiting the therapeutic potential of glycoconjugates. (2006) (137)
- Resistance of Transmitted Founder HIV-1 to IFITM-Mediated Restriction (2016) (136)
- Structural Constraints Determine the Glycosylation of HIV-1 Envelope Trimers. (2015) (128)
- Comparative assessment of multiple COVID-19 serological technologies supports continued evaluation of point-of-care lateral flow assays in hospital and community healthcare settings (2020) (115)
- Glycan clustering stabilizes the mannose patch of HIV-1 and preserves vulnerability to broadly neutralizing antibodies (2015) (115)
- Defining criteria for oligomannose immunogens for HIV using icosahedral virus capsid scaffolds. (2010) (113)
- The effect of methotrexate and targeted immunosuppression on humoral and cellular immune responses to the COVID-19 vaccine BNT162b2: a cohort study (2021) (110)
- The Polybasic Cleavage Site in SARS-CoV-2 Spike Modulates Viral Sensitivity to Type I Interferon and IFITM2 (2021) (102)
- The HIV glycan shield as a target for broadly neutralizing antibodies (2015) (101)
- SARS-CoV-2 RNAemia and proteomic trajectories inform prognostication in COVID-19 patients admitted to intensive care (2021) (96)
- A nonself sugar mimic of the HIV glycan shield shows enhanced antigenicity (2010) (90)
- Long COVID burden and risk factors in 10 UK longitudinal studies and electronic health records (2022) (83)
- Acute Immune Signatures and Their Legacies in Severe Acute Respiratory Syndrome Coronavirus-2 Infected Cancer Patients (2021) (82)
- Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant (2021) (82)
- Two Classes of Broadly Neutralizing Antibodies within a Single Lineage Directed to the High-Mannose Patch of HIV Envelope (2014) (81)
- Comparative performance of SARS-CoV-2 lateral flow antigen tests and association with detection of infectious virus in clinical specimens: a single-centre laboratory evaluation study (2021) (79)
- Antibody 2G12 Recognizes Di-Mannose Equivalently in Domain- and Nondomain-Exchanged Forms but Only Binds the HIV-1 Glycan Shield if Domain Exchanged (2010) (76)
- Targeting host-derived glycans on enveloped viruses for antibody-based vaccine design. (2015) (75)
- Cell- and Protein-Directed Glycosylation of Native Cleaved HIV-1 Envelope (2015) (74)
- Incomplete Neutralization and Deviation from Sigmoidal Neutralization Curves for HIV Broadly Neutralizing Monoclonal Antibodies (2015) (74)
- Polysaccharide mimicry of the epitope of the broadly neutralizing anti-HIV antibody, 2G12, induces enhanced antibody responses to self oligomannose glycans. (2010) (73)
- SARS-CoV-2 can recruit a heme metabolite to evade antibody immunity (2021) (68)
- Protein and Glycan Mimicry in HIV Vaccine Design (2019) (68)
- Neutralizing antibody activity in convalescent sera from infection in humans with SARS-CoV-2 and variants of concern (2021) (65)
- Anti-HIV B Cell Lines as Candidate Vaccine Biosensors (2012) (58)
- Atomic-scale detection of organic molecules coupled to single-walled carbon nanotubes. (2007) (56)
- Interim results of the safety and immune-efficacy of 1 versus 2 doses of COVID-19 vaccine BNT162b2 for cancer patients in the context of the UK vaccine priority guidelines (2021) (51)
- Estimates of the rate of infection and asymptomatic COVID-19 disease in a population sample from SE England (2020) (51)
- Risk factors for long COVID: analyses of 10 longitudinal studies and electronic health records in the UK (2021) (51)
- Single dose of BNT162b2 mRNA vaccine against severe acute respiratory syndrome coronavirus‐2 (SARS‐CoV‐2) induces neutralising antibody and polyfunctional T‐cell responses in patients with chronic myeloid leukaemia (2021) (47)
- Very Few Substitutions in a Germ Line Antibody Are Required To Initiate Significant Domain Exchange (2010) (46)
- A consensus Covid-19 immune signature combines immuno-protection with discrete sepsis-like traits associated with poor prognosis (2020) (45)
- Single dose of BNT162b2 mRNA vaccine against SARS-CoV-2 induces high frequency of neutralising antibody and polyfunctional T-cell responses in patients with myeloproliferative neoplasms (2021) (42)
- B Cells from Knock-in Mice Expressing Broadly Neutralizing HIV Antibody b12 Carry an Innocuous B Cell Receptor Responsive to HIV Vaccine Candidates (2013) (41)
- Humoral and cellular immunogenicity to a second dose of COVID-19 vaccine BNT162b2 in people receiving methotrexate or targeted immunosuppression: a longitudinal cohort study (2021) (40)
- The legacy of maternal SARS-CoV-2 infection on the immunology of the neonate (2021) (39)
- Direct deprotected glycosyl-asparagine ligation. (2006) (38)
- The Tetrameric Plant Lectin BanLec Neutralizes HIV through Bidentate Binding to Specific Viral Glycans. (2017) (38)
- A structural basis for antibody-mediated neutralization of Nipah virus reveals a site of vulnerability at the fusion glycoprotein apex (2019) (37)
- Mechanisms of escape from the PGT128 family of anti-HIV broadly neutralizing antibodies (2016) (35)
- HIV-1 Glycan Density Drives the Persistence of the Mannose Patch within an Infected Individual (2016) (34)
- A Protective Monoclonal Antibody Targets a Site of Vulnerability on the Surface of Rift Valley Fever Virus (2018) (33)
- Glycan Microheterogeneity at the PGT135 Antibody Recognition Site on HIV-1 gp120 Reveals a Molecular Mechanism for Neutralization Resistance (2015) (32)
- Impact of the B.1.1.7 variant on neutralizing monoclonal antibodies recognizing diverse epitopes on SARS-CoV-2 Spike (2021) (31)
- Convergent immunological solutions to Argentine hemorrhagic fever virus neutralization (2017) (31)
- Author Correction: A dynamic COVID-19 immune signature includes associations with poor prognosis (2020) (31)
- Ligand amplification in a dynamic combinatorial glycopeptide library. (2005) (30)
- Combined epidemiological and genomic analysis of nosocomial SARS-CoV-2 infection early in the pandemic and the role of unidentified cases in transmission (2021) (29)
- Site‐Selective Traceless Staudinger Ligation for Glycoprotein Synthesis Reveals Scope and Limitations (2011) (28)
- Reagent switchable stereoselective beta(1,2) mannoside mannosylation: OH-2 of mannose is a privileged acceptor. (2008) (24)
- Repeated vaccination against SARS-CoV-2 elicits robust polyfunctional T cell response in allogeneic stem cell transplantation recipients (2021) (24)
- Humoral and cellular immunity to delayed second dose of SARS-CoV-2 BNT162b2 mRNA vaccination in patients with cancer (2021) (24)
- Signature of Antibody Domain Exchange by Native Mass Spectrometry and Collision-Induced Unfolding. (2018) (23)
- Broad Neutralization of SARS-CoV-2 Variants, Including Omicron, following Breakthrough Infection with Delta in COVID-19-Vaccinated Individuals (2022) (22)
- Analysis of the dispersity in carbohydrate loading of synthetic glycoproteins using MALDI-TOF mass spectrometry. (2010) (21)
- 2G12-Expressing B Cell Lines May Aid in HIV Carbohydrate Vaccine Design Strategies (2012) (19)
- A dynamic COVID-19 immune signature includes associations with poor prognosis (2020) (14)
- SARS-CoV-2–specific memory B cells can persist in the elderly who have lost detectable neutralizing antibodies (2021) (14)
- Author Correction: A dynamic COVID-19 immune signature includes associations with poor prognosis (2020) (14)
- SARS-CoV-2 host-shutoff impacts innate NK cell functions, but antibody-dependent NK activity is strongly activated through non-spike antibodies (2022) (14)
- Folding of an MHC class II-restricted tumor antigen controls its antigenicity via MHC-guided processing (2007) (13)
- Real-world evaluation of a novel technology for quantitative simultaneous antibody detection against multiple SARS-CoV-2 antigens in a cohort of patients presenting with COVID-19 syndrome† †Electronic supplementary information (ESI) available. See DOI: 10.1039/d0an01066a (2020) (13)
- SARS-CoV-2 recruits a haem metabolite to evade antibody immunity (2021) (13)
- Determination of N-linked Glycosylation in Viral Glycoproteins by Negative Ion Mass Spectrometry and Ion Mobility. (2015) (11)
- Real-world evaluation of a novel technology for quantitative simultaneous antibody detection against multiple SARS-CoV-2 antigens in a cohort of patients presenting with COVID-19 syndrome † (2020) (11)
- "Polar patch" proteases as glycopeptiligases. (2005) (10)
- ADNKA overcomes SARS-CoV2-mediated NK cell inhibition through non-spike antibodies (2021) (10)
- A neutralizing epitope on the SD1 domain of SARS-CoV-2 spike targeted following infection and vaccination (2022) (10)
- Distinct antigenic properties of the SARS-CoV-2 Omicron lineages BA.4 and BA.5 (2022) (10)
- Clinical utility of targeted SARS-CoV-2 serology testing to aid the diagnosis and management of suspected missed, late or post-COVID-19 infection syndromes: Results from a pilot service implemented during the first pandemic wave (2020) (10)
- Rewritable glycochips. (2009) (10)
- Antibody longevity and cross-neutralizing activity following SARS-CoV-2 wave 1 and B.1.1.7 infections (2021) (8)
- Combined epidemiological and genomic analysis of nosocomial SARS-CoV-2 transmission identifies community social distancing as the dominant intervention reducing outbreaks (2020) (7)
- Resilient SARS-CoV-2 diagnostics workflows including viral heat inactivation (2021) (7)
- Molecular rationale for antibody-mediated targeting of the hantavirus fusion glycoprotein (2020) (7)
- Structural Basis for a Neutralizing Antibody Response Elicited by a Recombinant Hantaan Virus Gn Immunogen (2021) (6)
- Contrasting Modes of New World Arenavirus Neutralization by Immunization-Elicited Monoclonal Antibodies (2022) (6)
- The polybasic cleavage site in the SARS-CoV-2 spike modulates viral sensitivity to Type I IFN and IFITM2 (2020) (6)
- Translational Research in the Time of COVID-19—Dissolving Boundaries (2020) (5)
- Repeated vaccination against SARS-CoV-2 elicits robust polyfunctional T cell response in allogeneic stem cell transplantation recipients (2021) (5)
- Evidence for the heterologous benefits of prior BCG vaccination on COVISHIELD™ vaccine-induced immune responses in SARS-CoV-2 seronegative young Indian adults (2022) (5)
- SARS-CoV-2 RNAemia and proteomic biomarker trajectory inform prognostication in COVID-19 patients admitted to intensive care (2020) (5)
- Targeting Glycans on Human Pathogens for Vaccine Design. (2018) (5)
- SARS-CoV-2-Specific Memory B Cell Responses Are Maintained After Recovery from Natural Infection and Postvaccination. (2022) (4)
- Global patterns of antigen receptor repertoire disruption across adaptive immune compartments in COVID-19 (2022) (4)
- Evolutionary remodelling of N‐terminal domain loops fine‐tunes SARS‐CoV‐2 spike (2022) (4)
- SARS-CoV-2-specific memory B cells can persist in the elderly despite loss of neutralising antibodies (2021) (4)
- Omicron breakthrough infections in vaccinated or previously infected hamsters (2022) (4)
- ChAdOx1 nCoV-19 vaccine elicits monoclonal antibodies with cross-neutralizing activity against SARS-CoV-2 viral variants (2022) (4)
- BCG revaccination qualitatively and quantitatively enhances SARS-CoV-2 spike-specific neutralizing antibody and T cell responses induced by the COVISHIELD™ vaccine in SARS-CoV-2 seronegative young Indian adults (2022) (4)
- The effect of Omicron breakthrough infection and extended BNT162b2 booster dosing on neutralization breadth against SARS-CoV-2 variants of concern (2022) (4)
- Correction for Doores et al., Two Classes of Broadly Neutralizing Antibodies within a Single Lineage Directed to the High-Mannose Patch of HIV Envelope (2015) (3)
- Structural Constraints Det ermine the Glycosylation of HIV-1 Envelope Trimers Graphical (2015) (3)
- Impaired humoral and T cell response to vaccination against SARS-CoV-2 in chronic myeloproliferative neoplasm patients treated with ruxolitinib (2022) (3)
- Concordance of B‐ and T‐cell responses to SARS‐CoV‐2 infection, irrespective of symptoms suggestive of COVID‐19 (2022) (3)
- ACE2 expression in adipose tissue is associated with cardio-metabolic risk factors and cell type composition—implications for COVID-19 (2022) (3)
- Modular capsid decoration boosts adenovirus vaccine-induced humoral immunity against SARS-CoV-2 (2022) (3)
- Peripheral immunophenotypes in children with multisystem inflammatory syndrome associated with SARS-CoV-2 infection (2020) (2)
- Antibody levels following vaccination against SARS-CoV-2: associations with post-vaccination infection and risk factors in two UK longitudinal studies (2022) (2)
- Cross-reactivity of glycan-reactive HIV-1 broadly neutralizing antibodies with parasite glycans (2022) (2)
- BNT162b2 COVID-19 and ChAdOx1 nCoV-19 vaccination in patients with myelodysplastic syndromes (2022) (2)
- Single dose of BNT162b2 mRNA vaccine against SARS-CoV2 induces neutralizing antibody and polyfunctional T-cell responses in patients with CML (2021) (2)
- Structural dynamics in the evolution of SARS-CoV-2 spike glycoprotein (2023) (2)
- Molecular rationale for hantavirus neutralization by a reservoir host-derived monoclonal antibody (2020) (2)
- Harnessing post-translational modifications for next-generation HIV immunogens. (2018) (2)
- Modular capsid decoration boosts adenovirus vaccine-induced humoral and cellular immunity against SARS-CoV-2 (2022) (1)
- HIV Glycomics and Glycoproteomics (2014) (1)
- 055 The impact of methotrexate and targeted immunosuppression on cellular and humoral immune responses to COVID-19 vaccine BNT162b2: a cohort study (2021) (1)
- Immunophenotyping of Circulating Leukocytes Reveal Non-specific Activation of Innate and Adaptive Immune Systems in Multi-System Inflammatory Syndrome of Childhood Temporally Associated with SARS-Cov-2 Infection: Descriptive Cohort Study (2020) (1)
- The Cambrian Conundrum: Early Divergence and Later Ecological Success in the Early History of Animals (2011) (1)
- Direct Deprotected Glycosyl—Asparagine Ligation. (2006) (1)
- A monoclonal antibody targeting the Nipah virus fusion glycoprotein apex imparts protection from disease (2022) (0)
- Pre-Pandemic Plasma IL-6 Levels are Positively Associated with Chronic Fatigue But Do Not Differentiate Those with COVID-19 Induced Fatigue (2022) (0)
- Cover Picture: Exploring and Exploiting the Therapeutic Potential of Glycoconjugates (Chem. Eur. J. 3/2006) (2006) (0)
- Broadly neutralizing antibody responses in the longitudinal primary HIV-1 infection Short Pulse Anti-Retroviral Therapy at Seroconversion cohort (2021) (0)
- ChAdOx1 nCoV-19 (AZD1222) vaccine elicits monoclonal antibodies with potent cross-neutralizing activity against SARS-CoV-2 viral variants (2021) (0)
- Exploring and Exploiting the Therapeutic Potential of Glycoconjugates (2006) (0)
- Broad and potent neutralizing mAbs are elicited in vaccinated individuals following Delta/BA.1 breakthrough infection (2023) (0)
- Mechanisms of escape from the PGT128 family of anti-HIV broadly neutralizing antibodies (2016) (0)
- The Tetrameric Plant Lect in BanLec Neutralizes HIV through Bidentate Binding to Specific Viral Glycans Graphical (2018) (0)
- Erwin Success in the Early History of Animals The Cambrian Conundrum : Early Divergence and Later Ecological (2011) (0)
- Boosting of Waned Humoral and Cellular Responses to SARS-CoV-2 Variants of Concern Among Patients with Cancer (2022) (0)
- Trends in Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) infection and vaccine antibody prevalence in a multi-ethnic inner-city antenatal population: A cross-sectional surveillance study. (2023) (0)
- Long-COVID fatigue is not predicted by pre-pandemic plasma IL-6 levels in mild COVID-19 (2023) (0)
- Endogenous antibody responses in REGN-COV2-treated SARS-CoV-2-infected individuals (2023) (0)
- Low Frequency of T Cell and Antibody Responses to Vaccination Against Sars-Cov-2 in Patients Post Allogeneic Stem Cell Transplantation in Comparison with Chronic Myeloid Malignancy Patients (2021) (0)
- Title: Modular capsid decoration boosts adenovirus vaccine-induced humoral and cellular immunity against SARS-CoV-2 (2022) (0)
- SARS-CoV-2 RNAemia and proteomic biomarker trajectory inform 1 prognostication in COVID-19 patients admitted to intensive care 2 (2020) (0)
- P05-11. Yeast mannan genetics controls the molecular specificity of anti-carbohydrate antibodies cross-reactive to the HIV envelope (2009) (0)
- VelcroVax: a “Bolt-On” Vaccine Platform for Glycoprotein Display (2023) (0)
- Third-dose SARS-CoV-2 mRNA vaccine increases Omicron variant neutralisation in patients with chronic myeloid disorders (2022) (0)
- HIV-1 glycan density drives the persistence of the mannose patch within an infected 1 individual 2 3 (2016) (0)
- Author Correction: A dynamic COVID-19 immune signature includes associations with poor prognosis (2020) (0)
- Impaired humoral and T cell response to vaccination against SARS-CoV-2 in chronic myeloproliferative neoplasm patients treated with ruxolitinib (2022) (0)
- “Polar Patch” Proteases as Glycopeptiligases. (2005) (0)
- Deviation from standard dose-response curve by bnMAbs in a U87 target cell assay. (2015) (0)
- PLOS Pathogens 2017 Reviewer and Editorial Board Thank You (2018) (0)
- Junin virus GP1 glycoprotein in complex with an antibody Fab fragment (2017) (0)
- VelcroVax: a ‘bolt-on’ vaccine platform technology improves antibody titres against a viral glycoprotein in mice (2022) (0)
- Humoral and Cellular Immunity to SARS-CoV-2 Vaccination in Cancer Patients: Completed Prospective Observational Study Using BNT162b2 mRNA Vaccine (2021) (0)
- Broadly neutralizing antibody responses in the longitudinal primary HIV-1 infection SPARTAC cohort. (2021) (0)
- Crystal structure of Puumala virus Gc in complex with Fab 4G2 (2020) (0)
This paper list is powered by the following services:
Other Resources About Katie Doores
What Schools Are Affiliated With Katie Doores?
Katie Doores is affiliated with the following schools:
